Education
About Us
Working with TipRanks
Follow Us
TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
1875 Stock Chart & Stats
HK$2.50
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.50
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.52 - HK$4.66
Previous CloseN/A
Volume400.00
Average Volume (3M)240.51K
Market Cap
HK$3.25B
Enterprise ValueHK$2.89B
Total Cash (Recent Filing)HK$383.98M
Total Debt (Recent Filing)HK$397.20M
Price to Earnings (P/E)400.0
Beta0.52
Next Earnings
Mar 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)1.67
Price to Sales (P/S)1.11
P/FCF Ratio-170.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA relatively low debt-to-equity ratio and stable equity base provide durable financial flexibility for R&D and commercialization cycles. Strong balance sheet reduces refinancing and solvency risk, enabling continued investment in drug development and strategic partnerships over the next several quarters.
Profitability TurnaroundMargins moving from negative to positive and improved EBIT/EBITDA indicate structural operating improvements across cost control and pricing. Sustained positive margins support reinvestment capacity and make future product launches or scaling more financially viable over the coming 2–6 months.
Focused Biologics And Oncology FranchiseA focused franchise in oncology and immunology with biologics and monoclonal antibodies aligns with high, durable clinical need and pricing power. This specialization supports sustainable revenue opportunity, higher barriers to entry, and long-term partnerships with hospitals and pharma collaborators.
Bears Say
Persistent Negative Free Cash FlowContinued negative free cash flow signals that operating cash generation does not yet cover capital and growth spending, raising liquidity and financing risk. Over several months this can force external financing or cutbacks in R&D/commercialization, constraining strategic options.
Earnings Volatility / EPS DeclineA material decline in EPS highlights earnings volatility and potential pressure on profitability drivers. Persistent EPS contraction undermines internal funding for pipeline and commercialization, increasing reliance on external capital and exposing the company to execution risk over the medium term.
Historical Revenue VolatilityPrior periods of negative revenue growth suggest the business can experience operational or market setbacks. This history indicates execution and demand risk that could re-emerge, making forward revenue consistency and planning for launch milestones less certain over the next few quarters.
TOT BIOPHARM International Co. Ltd. News
1875 FAQ
What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?
TOT BIOPHARM International Co. Ltd. lowest stock price was HK$1.52 and its highest was HK$4.66 in the past 12 months.
What is TOT BIOPHARM International Co. Ltd.’s market cap?
TOT BIOPHARM International Co. Ltd.’s market cap is HK$3.25B.
When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?
TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Mar 24, 2026 which is in 30 days.
How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?
TOT BIOPHARM International Co. Ltd. released its earnings results on Aug 12, 2025. The company reported HK$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.011.
Is TOT BIOPHARM International Co. Ltd. overvalued?
According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Overvalued.
Does TOT BIOPHARM International Co. Ltd. pay dividends?
TOT BIOPHARM International Co. Ltd. does not currently pay dividends.
What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?
TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.
What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?
TOT BIOPHARM International Co. Ltd. reported an EPS of HK$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.113%.
Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1875
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TOT BIOPHARM International Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.06%
12-Months-Change
Fundamentals
Return on Equity
0.99%
Trailing 12-Months
Asset Growth
3.34%
Trailing 12-Months
Company Description
TOT BIOPHARM International Co. Ltd.
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.
Technical Analysis
Mabpharm Limited
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
Zhaoke Ophthalmology Ltd.
―
Immunotech Biopharm Ltd
―
Hightide Therapeutics Inc
―